1. Home
  2. AGEN vs BANX Comparison

AGEN vs BANX Comparison

Compare AGEN & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$5.00

Market Cap

208.2M

Sector

Health Care

ML Signal

HOLD

BANX

ArrowMark Financial Corp.

HOLD

Current Price

$20.01

Market Cap

191.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
BANX
Founded
1994
N/A
Country
United States
United States
Employees
81
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
208.2M
191.0M
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
AGEN
BANX
Price
$5.00
$20.01
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
8.0M
27.0K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
1.02
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.95
N/A
Revenue Growth
89.95
N/A
52 Week Low
$2.71
$18.45
52 Week High
$8.70
$23.67

Technical Indicators

Market Signals
Indicator
AGEN
BANX
Relative Strength Index (RSI) 65.37 65.61
Support Level $3.16 $19.24
Resistance Level N/A $20.26
Average True Range (ATR) 0.63 0.22
MACD 0.21 0.04
Stochastic Oscillator 35.63 81.56

Price Performance

Historical Comparison
AGEN
BANX

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

Share on Social Networks: